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Trypanosoma cruzi is the causative agent of Chagas disease. The lack of an efficient 
and safe treatment supports the research into novel metabolic targets, with the malic 
enzyme (ME) representing one such potential candidate. T. cruzi expresses a cytosolic 
(TcMEc) and a mitochondrial (TcMEm) ME isoform, with these activities functioning to 
generate NADPH, a key source of reducing equivalents that drives a range of anabolic 
and protective processes. To identify specific inhibitors that target TcMEs, two 
independent high-throughput screening strategies using a diversity library containing 
30,000 compounds were employed. IC50 values of 262 molecules were determined for 
both TcMEs as well as for three human ME isoforms, with the inhibitors clustered into six 
groups according to their chemical similarity. The most potent hits belonged to a 
sulfonamide group that specifically target TcMEc. Moreover, several selected inhibitors 
of both TcMEs showed trypanocidal effect against the replicative forms of T. cruzi. The 
chemical diversity observed among those compounds that inhibit TcMEs activity 
emphasizes the druggability of these enzymes, with a sulfonamide-based subset of 




American trypanosomiasis, also known as Chagas disease, is caused by the 
protozoan Trypanosoma cruzi. According to the WHO, up to 7 million people across Latin 
America are infected by this pathogen, with the disease now emerging as a problem at 
non-endemic sites1,2. The available treatments are based on the use of two 
nitroheterocycle prodrugs, nifurtimox and benznidazole. Although less toxic than 
nifurtimox, benznidazole displays side effects leading to discontinuation of treatment by 
around 30% patients3,4.   These prodrugs are curative against the initial acute stage of 
the disease with strains refractory to therapy being frequently encountered5,6. The use of 
benznidazole in chronic phase is still under investigation.7,8 Against this backdrop there 
is a need for the development of safer, efficacious drug treatments that target all stages 
of the disease. 
Reduced nicotinamide adenine dinucleotide phosphate (NADPH) has a crucial role in 
parasite survival. This co-factor is used as source of reducing equivalents to maintain 
trypanothione, the main free thiol found within this organism, in its reduced dihydro state. 
In this form trypanothione can drive a series of redox cascades that facilitate the 
detoxification of reactive oxygen species (ROS) produced from endogenous metabolic 
reactions or from exogenous immune insults generated by mammalian host cells9. 
Additionally, NADPH participates in a number of biosynthetic pathways, such as in fatty 
acid and nucleic acid synthesis10. As this co-factor plays an essential role in maintaining 
the reduced environment found within a cell and in the production of the basic building 
blocks required for cell viability, enzymes responsible for its generation are considered 
potential drug targets. In most organisms, the enzymes responsible for NADPH 
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production depend on intermediates derived from highly reduced substrates or with high 
energy-content.  For instance, this is the case of the pentose-phosphate pathway (PPP)11, 
which includes the reactions catalyzed by glucose-6-phosphate dehydrogenase 
(G6PDH), and 6-phosphogluconate dehydrogenase (6PGDH). The operability of this 
route relies on the supply of glucose-6-phosphate (G6P) to maintain the flux of NADPH 
generation. On the other hand, enzymes such as malic enzymes (MEs)12, isocitrate 
dehydrogenase (IDH)13 and glutamate dehydrogenase (GLDH)14 also represent 
important candidates for NADPH production, mainly when glucose is scarce and amino 
acids are utilized as alternative source for energy production15. 
T. cruzi energy metabolism changes according to the carbon source available in the 
different microenvironments the parasite finds itself during its life cycle16. In the infectious, 
non-replicative bloodstream trypomastigote form, the parasite is able to utilize the 
abundant glucose supply found in its mammalian host’s bloodstream. In contrast, the 
replicative intracellular amastigotes grow in almost free glucose medium, and are 
predicted to depend on amino acids catabolism for energy production. Considering the 
nutrient availability in the amastigotes stage, enzymes such as ME, IDH and GDH are 
likely to gain importance in NADPH production. 
Malic enzyme, in the presence of a divalent cation ions (Mg2+ or Mn2+), catalyzes the 
oxidative decarboxylation of malate to pyruvate, concomitantly reducing NAD(P)+ to 
NAD(P)H. T. cruzi and T. brucei expresses two ME isoforms, one located in the cytosol 
(TcMEc and TbMEc, respectively) and the other present in the mitochondrion (TcMEm 
and TbMEm, respectively)12. Down regulation of TbMEm expression using RNAi on T. 
brucei procyclic forms, the parasite stage found in the insect vector, has revealed that 
this isoform is essential for parasite survival whereas TbMEc along with the PPP is 
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responsible for NADPH production in the cytosol17. In T. cruzi, there is no information 
regarding the essentiality of the distinct ME isoforms. Although TcMEc and TbMEc 
catalyze the same reaction, both isozymes differ in their kinetic properties. TcMEc is 
allosterically activated by L-aspartate, a property that does not extend to the T. brucei 
counterpart. The allosteric regulation of TcMEc may reflect a relevant function of this 
isoform in T. cruzi metabolism. 
Herein, we present the discovery of 262 novel TcMEc and TcMEm inhibitors identified 
using a biochemical high-throughput screen (HTS). Based on their structure, most (250) 
were placed into 6 distinct chemical classes, while the remainder represent structurally 
unrelated compounds (singletons). Different compounds specifically targeted TcMEc or 
TcMEm without significantly affecting the activity of human ME isoforms, with several 
displaying a growth inhibition effect against cultured T. cruzi epimastigotes and 
amastigotes. 
 
Materials and Methods 
Chemicals 
The screening library DIVERSet™ and the ressuply compounds were purchased from 
Chembridge. Clostridium kluyveri diaphorase was obtained from Worthington 
Biochemical while resazurin, NADP+, NADPH, L-malic acid, L-aspartic acid, fumaric acid, 
MnCl2 and DMSO were purchased from Sigma-Aldrich. Tris-HCl and NaCl were acquired 




HsME expression constructs 
DNA fragments encoding for HsME1 (NM_002395), HsME2 (NP_002387) and HsME3 
(NM_001161586) were amplified from MDA-mB-231 breast cancer (for HsME1 and 
HsME3) or human fetal brain (for HsME2) cDNA using the primers 
GCGGATCCCATATGGAGCCCGAAGCCC and GCCTCGAGCTACTGGTCAACTTTGG 
TCTGTATTTTCTGC for HsME1, GCGGATCCCATATGTTGCACATAAAAGAAAAAGG 
CAAGCC and GCCTCGAGCTATTCTGTTATCACAGGAGGGCTTG for HsME2 and 
GCGAGCTCCATATGGTGCCCCTGAAGAAGCGC and GCCTCGAGTCAGACCGTCT 
GAACATTCATGGC for HsME3 (underlined sequences correspond to restriction sites 
incorporated into the oligonucleotides to facilitate cloning). For HsME2 and HsME3, the 
amplified fragments lacked regions that encode for the first 18 or 44 amino acids, 
respectively, sequences predicted to contain a mitochondrial target peptide (MTP)18,19: 
The MTP sequence for HsME3 was predicted using MitoPROII v.1.101 
(http://ihg.gsf.de/ihg/mitoprot.html). The human ME amplicons were cloned into the 
pGEM-T vector (Promega), sequenced before being subcloned into the NdeI and XhoI 
restriction sites of pET28a+.  
 
Protein expression and purification 
The TcMEs heterologous expression followed the protocol published elsewhere12. In 
the case of HsMEs, E. coli Rossetta (DE3) pLysS containing the expression vector 
(pET28_HsME1, pET28_HsME2 or pET28_HsME3) was cultured in the autoinduction 
ZYM5052 medium20, in the presence of 30 µg/mL kanamycin and 34 µg/mL 
chloramphenicol, at 22 °C for 60 hours. The cells were harvested and the pellets stored 
at -20°C. 
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The purification steps were the same for TcMEs and HsMEs. Cells were resuspended 
in buffer A (50 mM Tris-HCl pH 8.0, 500 mM NaCl) containing 5 mM imidazole and 
lysozyme (1 mg/mL). Following sonication, the clarified lysates were passed through a 
HisTrap HP column (GE Healthcare Life Technologies) and proteins eluted using an 
imidazole gradient (5 to 400 mM) in buffer A. ME-containing fractions were pooled and 
the proteins concentrated. The histidine tag was removed with thrombin (2 U/mg), for 16 
hours at 4°C. Finally, the proteins were subjected to size exclusion chromatography on a 
Superdex 200 16/60 column (GE Healthcare Life Technologies) equilibrated with GF 
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl). Purified proteins were concentrated using 
an Amicon Ultra-15 Centrifugal Filter device of 30 kDa molecular weight cutoff (Millipore) 
and stored at -80°C with 5% (v/v) glycerol.  
 
Kinetic characterization     
The malate oxidative decarboxylation activities of recombinant MEs were assayed in 
a coupled reaction using diaphorase and resazurin (Fig 1A). In this system, NADPH 
generated during the ME-catalyzed conversion of malate to pyruvate is utilized by 
diaphorase to drive reduction of resazurin to resorufin. Resorufin production can then be 
followed by monitoring the change in fluorescence using a plate reader set to an excitation 
 = 570 nm and an emission  = 590 nm. The apparent Michaelis-Menten constant 
(KmApp) for NADP+ or malate was determined by varying the concentration of one of the 
substrates while keeping the other at a saturating level. The activation constant (Ka) of 
aspartate for TcMEc was determined as previously described21. All the reactions were 
performed at 25°C in Reaction Buffer (50 mM Tris-HCl pH 7,5, 50 mM NaCl and 0.01% 
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(v/v) Triton X-100) supplemented with 2 mM MnCl2, 10 µM resazurin and 2 U/mL 
diaphorase, in 384-well black v-bottom microplates and a final volume of 50 µL. The 
resorufin fluorescence intensity was measured using an EnVision plate reader 
(PerkinElmer).   
 
Automated primary HTS 
The automated HTS assay for TcMEc and TcMEm was performed using the coupled 
system of diaphorase and resazurin, adapted from a previous reported dehydrogenase 
HTS assay22. The activity of either trypanosomal enzyme in the presence of a diversity 
chemical library of 29,760 compounds was assessed using a homogeneous end-point 
assay in 384-well plate format and performed in an automated workstation (liquid handler 
- JANUS-MDT, plate reader - EnVision – all from PerkinElmer). First, 22 µL Reaction Mix 
was added into the wells, followed by the transfer of 0.5 µL sample compound (stock at 
1 mM in 100% (v/v) DMSO). The reaction was then initiated by addition of 2.5 µL malate 
(concentrations are described below). Following incubation at room temperature for 3 
hours, the end-point fluorescence intensity of resorufin was measured (excitation  =570 
nm, emission  =590 nm). The Final Assay Concentration (FAC) of reagents for assaying 
TcMEm activity was as follows: 10 µM NADP+, 2 mM MnCl2, 10 µM resazurin, 1 U/mL 
diaphorase, 63 pM TcMEm and 1 mM malate. All plates contained 32 positive controls 
(Reaction Mix + DMSO + malate) and 32 negative controls (Reaction Mix + DMSO + 
Reaction Buffer). The fluorescence intensity readouts were normalized, considering the 
means of positive and negative controls in each plate as 100% and 0% of reminiscent 
activity (RA), respectively. The assay quality was evaluated by  the Z-factor23. The 
 9 
compounds with RA less than or equal to the cutoff RA was considered a hit candidate. 
The cutoff RA was defined as the average RA of all samples minus three standard 
deviation. For TcMEc-based reactions, the above assay was performed in the presence 
of L-aspartate (FAC = 400 µM) and using different concentrations of TcMEc (FAC = 25 
pM), NADP+ (FAC = 20 µM) and malate (FAC = 1.3 mM). 
 
Confirmation Assay 
The hit candidates were assayed against TcMEs and against diaphorase only, to 
exclude false positives and inhibitors of the coupled system. The hit candidates were 
transferred from the screening library plates to new assay plates and assayed in triplicate, 
monitoring the resorufin formation for 30 minutes. The calculated velocities were 
normalized using controls. For TcMEs, the assay conditions were the same for HTS 
assay, except 2x amount of enzyme (TcMEs and diaphorase) was used. For diaphorase 
only reactions, the assay concentration of reagents was 15 µM NADPH, 2 mM MnCl2, 10 
µM resazurin, 0.035 U/mL diaphorase. 
 
IC50 determination 
Initially, the effect of a single dose (80 µM) of hit compound against TcMEs, HsMEs 
and diaphorase was assessed. For those structures that inhibited ME function by > 50% 
without affecting diaphorase, the concentration of compound that inhibited ME activity 
(IC50) by 50% was determined. First, the selected compounds were serially diluted (2.5-
fold dilution steps) in DMSO using a Versette Automated Liquid Handler (ThermoFischer 
Scientific). Next, the Reaction Mix and compounds were dispensed in 384-well plates 
using the Versette Automated Liquid Handler and the reaction was initiated with malate 
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using MultidropCombi Reagent Dispenser (ThermoFischer Scientific). The FAC for each 
compound were 80, 32, 12.8, 5.12, 2.05, 0.82, 0.328, 0.13, 0.052, 0.021, 0.008 and 0 µM. 
The velocity of resorufin formation was followed using a Clariostar microplate reader 
(BMG LABTECH), following manufacturer instructions for resorufin fluorescence 
(excitation  = 545 nm; emission  = 600 nm). The data were normalized with controls 
and analyzed in GraphPad Prism 5, using a sigmoidal curve. 
For TcMEs, the reagents concentrations were the same used in the Confirmation 
Assay, while for human MEs, the above inhibition assays were performed using 6 µM 
NADP+ and 4.7 mM malate for HsME1 (2.5 nM)-based assay; 1 mM NADP+, 0.7 mM 
fumarate and 4.5 mM malate in reactions containing HsME2 (12.5 nM) and 10 µM NADP+ 
and 3.4 mM malate were used when testing HsME3 (1.25 nM): all the reaction mixtures 
contained 2 mM MnCl2, 10 µM resazurin and 1 U/mL diaphorase. 
 
Mechanism of inhibition 
The mechanism of inhibition was established for TcMEm, by determining the 
Michaelis-Menten saturation curves for malate or NADP+ in the presence of 4 different 
concentrations of inhibitor, and with DMSO as control. This enzyme was used because 
its activity is not effected by L-aspartate while the inhibitors analysed exhibited inhibition 
for either TcMEs. The resultant curves were fitted to non-linear inhibition model by using 
GraphPad Prism 5 (GraphPad Software) from which the apparent inhibition constant KiApp 
was obtained. The inhibitory mechanism was considered the one with the model with the 
higher r2 ( > 0.98). The Lineweaver-Burk plots were also used to qualitatively assess the 




The L6 rat myoblast cell line was cultured at 37°C under a 5% (v/v) CO2 atmosphere 
in RPMI-1640 supplemented with 5 g/L HEPES pH 8.0, 0.34 g/L sodium glutamate, 0.22 
g/L sodium pyruvate, 2500 U/L penicillin, 0.25 g/L streptomycin and 10% (v/v) heat 
inactivated foetal calf serum. 
The T. cruzi (strain Y) epimastigote cells were grown at 27°C in Liver Infusion Tryptose 
medium 24 supplemented with 10% (v/v) heat inactivated foetal calf serum. T. cruzi (strain 
Sylvio X10/6) epimastigotes engineered to express the thermostable red-shifted firefly 
luciferase (PpyRE9h)25 were cultured at 27°C in RPMI-1640 containing 5 g/L trypticase, 
20 mg/L heamin, 5 g/L HEPES pH 8.0, 0.34 g/L sodium glutamate, 0.22 g/L sodium 
pyruvate, 2500 U/L penicillin, 0.25 g/L streptomycin and 10% (v/v) heat inactivated foetal 
calf serum. Infection of L6 monolayers with recombinant T. cruzi and the culturing of 
amastigote parasites was carried out as previously described26.  
 
Antiproliferative assays 
All assays were performed in a 96-well plate format. To determine mammalian 
cytotoxicity, growth medium (200 µL) containing 1500 L6 cells and different 
concentrations of compound (80 to 0.82 µM) were incubated at 37°C for 96 hours. 
Resazurin (FAC = 50 µM) was added to each well and cultures incubated for a further 6 
hours. The fluorescence of each culture was determined using a Gemini fluorescent plate 
reader (Molecular Devices) (excitation  = 530 nm, emission  = 585 nm, filter cutoff at 
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550) with the change in fluorescence resulting from the reduction of resazurin to resorufin 
being proportional to the number of live cells. The compound concentration that inhibits 
cell growth by 50% (EC50L6) was established using the non-linear regression tool on 
GraphPad Prism 5 (GraphPad Software). 
 
Growth inhibition assays against T. cruzi (strain Y) epimastigotes was performed using 
the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) as 
described22. Initial screens were performed in the presence of 80 µM compound with the 
trypanocidal activity scored as active, moderate or inactive when the % viable cells was 
<25%, between 25% and 75%, or >75%, respectively. For active structures, parasite 
growth was evaluated using different compound concentrations (80 to 0.82 µM) and from 
the resulting dose-response curve, a compound’s EC50Epi established. 
 
Growth inhibition assays against luciferase expressing T. cruzi amastigotes was 
performed as previously described26. Briefly, L6 (1500) cells in mammalian growth 
medium (100 µL) were allowed to adhere to the base of each well for 6 hours. T. cruzi 
trypomastigotes (10,000 in 100 µL mammalian growth medium) were then added to 
monolayer, and infections performed overnight at 37°C under 5% (v/v) CO2. The cultures 
were washed in growth medium to remove non-internalized parasites, treated with 
compound-containing fresh growth medium and subsequently incubated at 37°C under 
5% (v/v) CO2 for 72 hours. Growth medium was removed, the cells lysed in cell culture 
lysis reagent (Promega) and reporter levels determined using the Luciferase Assay kit 
(Promega). Luminescence was then measured using a Fluostar Omega plate reader 




 The HTS output was analyzed using Microsoft Office 365. JChem for Office was 
used for chemical database access, search and reporting (JChem for Office 16.8.2200). 
Analysis of the kinetic data, inhibition mechanism, IC50 and EC50 values were analyzed 




Automated primary HTS 
 Recombinant TcMEc and TcMEm were purified and their kinetic parameters 
determined under the HTS assay conditions (Fig S1, S1 Table). The L-aspartate 
activation constant (KA) was determined for the recombinant TcMEc; KA value = 400 ± 40 
µM. Using this data, the ME coupled reaction was then optimized for the end-point HTS 
assay. Once appropriately adapted, the inhibitory effect of a diverse chemical library 
containing 29,760 structures was evaluated on each trypanosomal enzyme using a single 
concentration (20 µM) of compound. Average Z-factor values were 0.85 ± 0.03 and 0.80 
± 0.04 for TcMEc and TcMEm, respectively. 631 (RA ≤ 57.7%) and 478 (RA ≤ 56.1%) hit 
candidates were identified for TcMEc and for TcMEm, respectively, with 287 molecules 
inhibiting both enzymes.  
The hit candidates were transferred from the screening library plates to new assay 
plates and assayed in triplicate against ME coupled assay and against diaphorase, both 
in kinetic mode. Confirmed hits fulfilled the following criteria: ME inhibition (RAME ≤ 50%), 
inactive against diaphorase (RAdiaphorase ≥ 80%) and time independent inhibition (ME 
activity linear along the assay time). Following these criteria, 287 and 74 hits were 
confirmed for TcMEc and TcMEm, respectively, with 27 common for both enzymes. 
 
Kinetic characterization of hits  
The most potent hits (RAME ≤ 30%) together with 99 commercially available analogues, 
totalizing 308 molecules, were resupplied. This compound collection was then assayed 
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in triplicate against both TcMEs, the three HsMEs and diaphorase, at 80 µM. The DNA 
fragments encoding for the catalytic regions of HsME1, HsME2 and HsME3 were 
heterologously expressed in E. coli, each enzyme purified and their kinetic parameters 
determined (S1 Table). These biochemical screens revealed that 262 compounds 
inhibited at least one of the T. cruzi MEs without affecting diaphorase activity: seven 
molecules were eliminated due to their inhibitory effect on diaphorase and 39 compounds 
did not inhibit TcMEs activity. For the ME specific inhibitors, IC50 values of each 
compound towards the TcMEs and HsMEs were determined (Fig 2, S2 Table). For 
TcMEm, the IC50 values ranged from 0.5 to 71 µM while for TcMEc this varied from 0.0032 
to 64 µM (Fig S2). Many compounds in the “resupply” library also inhibited at least one of 
the human MEs although encouragingly some were inactive against all three mammalian 
isoforms. Based on their chemical backbone and ability to target the trypanosomal 
enzyme, the compounds that constitute the “resupply” library could be clustered into 6 
structurally related different groups, designated as ATR1 to ATR6, with a seventh 
assemblage consisting of 12 non-structurally related singletons, designated as ATR7 (Fig 
2).  
To determine their mechanism of inhibition, a representative member from each 
structural group that generated an IC50 values ≤ 10 µM (ATR2-001, ATR3-001, ATR4-
001 and ATR5-001) was tested against TcMEm: this isoform was used as unlike TcMEc, 
its does not undergo allosteric activation thereby simplifying interpretation of the inhibition 
data. For ATR3-001 and ATR5-001, a mixed-type inhibition with respect to both 
substrates was noted (Fig S3). In contrast, TcMEm activity in the presence of ATR2-001 
resulted in a competitive inhibitory mechanism towards malate and mixed-type to NADP+ 
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whereas ATR4-001-treated enzyme was competitive to malate and uncompetitive to 
NADP+ (Fig S4). 
In vitro T. cruzi antiproliferative assays 
To determine whether any of the TcME inhibitors displayed anti-parasitic properties, a 
selected subset of compounds were screened for trypanocidal activity against cultured T. 
cruzi epimastigotes. The compounds used were selected based on their IC50 values 
towards the trypanosomal enzymes: The structures tested generated IC50 <15 µM against 
one or both TcMEs (ATR1, 2, 4-7), while a range (20 out of 183) of ATR3 compounds 
that elicited IC50 values ranging from 3 nM to 10 µM were screened. Out of the 44 agents 
examined, 13 displayed moderate trypanocidal effect at 80 µM with 21 having no 
significant effect on parasite growth at this concentration (S2 Table). For the remaining 
10 active compounds (Fig 3), growth inhibition assays were conducted to determine their 
potency against epimastigote parasites, yielding EC50Epi values ranging from 14 to 56 µM 
(Table 1). In parallel, benznidazole used as a control treatment, generated an EC50Epi of 
12 ± 1 µM. The biological activity of the 10 active compounds, was extended to evaluate 
their toxicity towards mammalian cells and T. cruzi amastigotes. Against the rat skeletal 
L6 line, 2 compounds (ATR5-001 and ATR7-005) had no effect on mammalian cell growth 
at concentrations up to 80 µM while the remaining 8 structures yielded EC50L6 values 
ranging from 14 to 55 µM (Table 1). When tested against T. cruzi amastigotes and using 
a single compound dosage at a concentration that did not affect host cell growth, 4 
molecules (ATR3-128, ATR6-001, ATR7-005 and ATR7-008) displayed anti-parasitic 
activity, preventing growth of the intracellular pathogen by >90% relative to untreated 
controls (Table 1). 
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Discussion 
The TcMEs are a promising drug target for Chagas disease treatment, due to their 
importance in helping maintain NADPH levels in the T. cruzi parasite. In this study, using 
a biochemical HTS we evaluated approximately 30,000 compounds as potential TcMEs 
inhibitors. A total of 262 compounds were identified and confirmed as blocking this activity 
with the hits falling into 6 groups of structurally related molecules and a group with 12 
singletons. The results obtained for each group is discussed below. 
The 3 compounds that comprise the ATR1 group all contain a benzyl-xanthine core 
within their backbone (Fig 2), with this type of scaffold already described as inhibitors of 
human BRAF protein kinase27. Here, members of this family presented moderate 
inhibitory activity towards the TcMEs (IC50 values of 12-48 µM) and HsME2 & 3 (IC50 
around 18 µM), with no effect on HsME1. For one of the ATR1s, ATR1-003, the presence 
of a sulfhydryl group attached to an imidazole ring on the xanthine backbone appears to 
underlie its mode of TcME inhibition: the ATR1-003 related compounds, ATR1-004 and 
ATR1-005, that contain a hydrogen or thiomethyl side chain at R1, have no affected 
enzyme function (Fig 4A). Unfortunately, none of the ATR1s screened against T. cruzi 
epimastigotes had any effect on parasite growth. 
All 7 ATR2s, which contain a tetrazol-yl 4 quinolinecarboxamide or N-1H-tetrazol-5-yl-
9H-xanthene-9-carboxamide core, proved to be general ME inhibitors targeting each 
parasite and mammalian isoform tested. Intriguingly, some of these compounds were up 
to ~5-fold more selective towards TcMEm relative to the other enzymes. Despite only 
determining the IC50 values of a limited number of ATR2s, it is clear that different ring-
based substituents at the R1 position on the conserved quinoline does not affect a 
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compounds inhibition potency (Fig 4B): ATR2-004, ATR2-006 and ATR2-007 all exhibit 
similar IC50 values towards TcMEc or TcMEm even though the former contains a tri-cyclic 
xanthene structure whereas the remaining two compounds possess a benzyl or 
thiophene moiety linked to the bicyclic quinolone ring. As with the ATR1 structures 
samples, no ATR2 compound displayed trypanocidal activity.  
The ATR3 compounds are related in that they possess a sulfonamide linker that 
connects two aromatic rings (5 or 6 membered). A total of 218 structures were identified 
as inhibiting the trypanosomal MEs with most (212) only targeting TcMEc. Of these, many 
generated an IC50 below 100 nM with ATR3-007 yielding a value of 3.2 nM. When the 
potency of these compounds towards the human ME isoforms was examined, 189 had 
no effect on any of the mammalian enzymes further demonstrating the specificity of these 
inhibitors towards TcMEc. This way, a preliminary structure-activity relationship (SAR) 
analysis is presented for the most potent compounds, with IC50 values below 100 nM (Fig 
5). 
Despite the variety of chemical structures of the 27 ATR3 compounds yielding IC50 
below 100 nM, 19 contain a nitrogen atom within a 6- or 5-memebered ring, two ligations 
apart from N-sulfonamide. The addition of this nitrogen to ATR3-152, rendering ATR3-
010, was sufficient to improve compounds potency by 912-fold. Less dramatic, but 
following the same behaviour, was the 5.8-fold gain in potency of compound ATR3-063, 
compared to ATR3-127. The addition of another nitrogen atom in the ring has deleterious 
effect for inhibitory activity, as seen in compound ATR3-055, that is 8.5-fold less potent 
than ATR3-026. Other orientations of the N-pyridinyl ring were found, as in ATR3-170 
and ATR3-188 (nitrogen located 3 ligations apart from N-sulfonamide), and in ATR3-003, 
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ATR3-004 and ATR3-153 (nitrogen 4 ligations apart from N-sulfonamide), all these 
inhibitors exhibited IC50 values in the micromolar range (S2 Table). Interestingly, ATR3-
003 and ATR3-004 inhibited TcMEm as well. In the subgroup of N-(2-pyridinyl)-
benzenesulfonamides (A = N, Fig 2), the following substituents in the pyridinyl ring were 
found: methyl at R7, R8 and R9 (also concomitantly at R7 and R9), and halogens 
(chlorine and bromine) at R8. However no compound with a substituent at R6 was 
identified. Analysing analogues of ATR3-020, the higher activity provided by the addition 
of chlorine at R8 is noteworthy. Likewise, from the 14 compounds of this subclass with an 
IC50 values below 100 nM, 10 have a halogen atom at R8. Regarding the benzene region, 
different substituents were found at all the positions of the ring. For instance, halogens, 
alkyl, methoxy and ethoxy, including a fused ring (ATR3-007) as well as another ring 
connected by a carboxamide (ATR3-002) were recognized. The presence of a chlorine 
at R3 (ATR3-026) improved activity in at least 50-fold compared to trifluoromethoxy 
(ATR3-113) and amine (ATR3-157) (Fig 5).    
Another representative ATR3 subgroup, presented among the most potent inhibitors, 
was formed by 4-(methylsulfanyl)-N-phenylbenzenesulfonamides (R3 = methylsulfanyl). 
Comparison of ATR3-028 analogues revealed the trend Br = Cl > F > Methyl > Methoxy 
for inhibitory activity, showing a preference for halogens at R8. The same occurs at 
position R7, where the replacement of methyl (ATR3-072) for chlorine (ATR3-028) 
improved potency by 10.8 fold. In the screened library, no compounds from this subgroup 
had substituents at positions R1, R2, R4 and R5. In contrast, within the subgroup of 4-
(methoxy)-N-phenylbenzenesulfonamides (R3 = methoxy), inhibitors with halogens 
(chlorine, fluorine, iodine), methyl or amide at R2 were identified. Again, as seen for the 
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other subgroups, the presence of a halogen atom at R8 (ATR3-039 and ATR3-061 as 
compared to ATR3-150) increased the inhibitory activity in one order of magnitude. 
Beside these subgroups, 3 compounds with a benzoic acid connected to N-sulfonamide 
were active in concentrations in the nanomolar range (< 100 nM). The substitution of an 
acid group at R6 enhances 40-fold the potency (ATR3-130 – ATR3-017). The acid 
position in the ring affected dramatically the activity, as seen in compound ATR3-210, 
2000-fold less potent than ATR3-017 (Fig 5).  
In addition to being able to block TcMEc activity, ATR3 compounds also displayed anti-
trypanosomal activity against epimastigote (ATR3-045, ATR3-073 and ATR3-128) and 
amastigote (ATR3-128) forms of T. cruzi (Table 1). Sulfonamide-based drugs are 
frequently used to treat various bacterial and protozoal infections, blocking 
dihydropteroate synthetase (DHPS) activity and therefore preventing folate synthesis. It 
is unlikely that the trypanocidal mode of action of the ATR3 structures identified here 
involves DHPS inhibition as T. cruzi is auxotrophic for folates and pterins28. Interestingly, 
sulfonamides similar to the ATR3 TcMEc inhibitors are also present in the reported GSK 
Chagas Box, a set of 222 lead-like molecules that came out of a phenotypic HTS using a 
library of 1.8 million compounds29.  A preliminary assay of TcMEs against the GSK 
Chagas Box confirmed 3 sulfonamides as potent inhibitors of TcMEc (data not shown). 
These data, together with the results reported here, encourage further phenotypic studies 
with the ATR3 dataset to evaluate possible correlation between TcMEc inhibition and 
parasite death. 
 Out of all the TcMEs inhibitor hits, the pyrimidinone-based ATR4 compounds 
demonstrated the highest selectivity towards TcMEm. Two of these specifically blocked 
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the activity of this trypanosomal isoform, including one (ATR4-003) that displayed 
trypanocidal properties against T. cruzi epimastigotes (Table 1; Fig 3). Unfortunately, 
ATR4-003 also exhibited toxicity to mammalian cells and did not affect T. cruzi amastigote 
growth. This group displayed the best behaviour regarding the inhibition mechanism, 
which was competitive with respect to malate and uncompetitive with respect to NADP+. 
This feature indicates a sequential binding of NADP+, followed by the inhibitor, which 
occupies the malate site. Interestingly, ATR4-like compounds are reported to inhibit the 
1-deoxy-D-xylulose-5-phosphate synthase from Mycobacterium tuberculosis (MtDXS)30. 
This enzyme participates in the mevalonate-independent, isoprenoid biosynthesis 
pathway utilizing pyruvate (ME product) and D-glyceraldehyde 3-phosphate to produce 
1-deoxy-D-xylulose-5-phosphate31. As T. cruzi synthesizes isoprenoids via a 
mevalonate-dependent pathway32 and apparently lacks a DXS homologue, it is unlikely 
that ATR4 targets this type of activity within cultured parasites. 
The ATR5 group comprises 12 structures distinguished by the presence of an 
azatricyclo decenedione motif. Generally, they function as moderate TcMEm, TcMEc, 
HsME2 and HsME3 inhibitors, with none affecting HsME1 activity. Some compounds that 
affect both trypanosomal enzymes appear to show a degree of selectivity (~ 5- to 8-fold) 
towards TcMEm. One of the compounds (ATR5-001) that specifically targets TcMEm 
displays growth inhibitory activity against T. cruzi epimastigotes (EC50Epi of 14.1 µM) 
(Table 1) while having no cytotoxic effect on mammalian cells. However, ATR5-001 was 
inactive against intracellular parasites. Compounds related to ATR5 have been reported 
to be inhibitors of thioredoxin glutathione reductase expressed by Schistosoma mansoni, 
with such structures being particularly effective against this parasites larva stage33.  
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The four active ATR6 molecules are of interest as they have no activity towards any of 
the HsMEs and displayed specific inhibition against TcMEm (ATR6-001 and ATR6-004) 
or TcMEc (ATR6-002 and ATR6-003) (Fig 2). The TcMEm preference appears to be due 
to the presence of a heterocyclic ring (pyridine or morpholine) at position R1 while smaller 
side chains (amine or ethoxy) confers selectivity towards TcMEc (Fig 4C). Encouragingly, 
ATR6-001 displays activity against T. cruzi epimastigotes and amastigotes. Given that 
very few members of compound group were tested, the generation of ATR6 derivatives 
will aid in understanding how this class of chemicals interact with TcMEm or TcMEc. This 
coupled with further phenotypic screens may lead to the identification of more potent 
trypanocidal ATR6 structures that exhibit low toxicity to mammalian cells. 
In addition to the structurally related compounds, a total of 12 unrelated chemicals 
(singletons) were identified from the HTS as inhibiting TcMEm and/or TcMEc with these 
being assigned to the ATR7 group. Most showed TcME inhibition specificity (9 targeted 
only TcMEc while 2 were specific for TcMEm) with these structures having no effect on 
mammalian enzyme activity. Only 1 compound (ATR7-010) blocked the activity of both 
trypanosomal enzymes with this effect extending across to all mammalian counterparts. 
Out of the 12 ATR7 variants, the most promising were ATR7-005 and ATR7-008. These 
both showed activity against T. cruzi epimastigotes and amastigotes with the former 
having displayed no cytotoxic effect against mammalian cells at the highest concentration 
assayed (80 uM).  
The variety of compounds discovered here demonstrates that TcMEs are 
amenable to drug-like compounds inhibition. This is an essential feature of a drug target, 
and the T. cruzi MEs were assessed for the first time in this context. An intriguing feature 
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to emerge from this work stems from the high number of potent (IC50 values in nanomolar 
range) TcMEc specific inhibitors identified from the screens relative to those that target 
TcMEm, indicating that cytosolic isoform may be more druggable that the mitochondrial 
variant. It is tempting to speculate that the higher availability of inhibitors targeting TcMEc 
may correlate with the presence of the allosteric site for aspartate. The fact that specific 
inhibitors for the two isoforms display trypanocidal effect suggests that both TcMEs may 
be essential for the parasite survival. Further experiments to assess target specificity of 
the identified molecules are required to confirm the essentiality of both TcME isoforms.  
This work reports the first set of inhibitors against TcMEs in addition to the 
trypanocidal activity of these compounds towards the intracellular stage of this pathogen. 
This medically relevant developmental stage represents the most important target for anti-
parasite therapies. Furthermore, new efforts in structural studies are required to identify 
the binding sites of the inhibitors on TcMEs molecules, especially regarding the 
compounds of ATR3 class. Besides, an expansion of the in vitro antitrypanosomal studies 
is also important to optimize the best trypanocidal drug. Lastly, also further studies to 
evaluate if the observed effects are due to an off target contribution will represent 
significant progress to defeat the neglected disease caused by this pathogen. 
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activity TcMEm TcMEc HsMEs 
ATR3-045 >80.00 0.32 ± 0.01 53.00 ± 10.002 23 ± 6 
36 ± 5 
[12.8] 
Inactive 
ATR3-073 >80.00 0.87 ± 0.00 >80.00 14 ± 2 
26 ± 3 
[12.8] 
Inactive 
ATR3-128 >80.00 3.80 ± 0.06 >80.00 41 ± 8 
54 ± 5 
[32] 
Active  at 
32 µM 
ATR4-003 5.10 ± 0.50 >80.00 >80.00 48 ± 6 
14 ± 1 
[5.1] 
Inactive 




ATR6-001 13.00 ± 1.00 >80.00 >80.00 29 ± 5 
55 ± 9 
[32] 
Active  at 
32 µM 
ATR7-005 >80.00 5.70 ± 0.30 >80.00 56 ± 8 
> 80 
[80] 
Active  at 
80 µM 
ATR7-006 >80.00 6.30 ± 0.50 >80.00 33 ± 5 
15 ± 2 
[5.1] 
Inactive 
ATR7-008 >80.00 8.90 ± 0.90 >80.00 19 ± 1 
53 ± 10 
[32] 
Active  at 
32 µM 
ATR7-010 3.80 ± 0.10 7.60 ± 0.40 
13.0 ± 1.001 
9.70 ± 0.802 
11.50 ± 0.503 
39 ± 4 




#IC50 for TcMEm, TcMEm, HsME1(1), HsME2(2) and HsME3(3) are shown. When the IC50 value is different 
than >80 µM, the value and isoform is indicated. 
The growth inhibitory effects of the selected compounds against cultured T. cruzi epimatigotes (EC50Epi), 
towards the mammalian L6 line (EC50L6) and against the amastigote are shown. In the EC50L6 column, the 
values in square brackets represents the safe concentration [SC], defined as the highest compound 
concentration assayed which displayed less than 10% cytotoxicity against L6. For the amastigote activity, 




Figure 1: Schematic of high throughput screening assay and workflow. A: The 
activities of the malic enzyme (ME) and diaphorase were coupled through the 
formation/utilization of NADPH. In this system, malate is converted to pyruvate in a 
reaction catalyzed by NADP+-dependent ME. The resultant NADPH is then utilized by 
diaphorase to reduce reasazurin to resorufin resulting in the reformation of NADP+. 
Resorufin formation can be followed by following the change in fluorescence. B: Flowchart 
diagram of HTS and characterization of hits. For more details, see Materials and Methods. 
  
Figure 2: Scaffold of TcMEs inhibitors groups. TcME inhibitors were clustered into 6 
structurally related groups (ATR1-6). The distinguishing chemical motifs and number (n) 
of compounds for each grouping are shown. The potency range (as judge by IC50) and 
number of compounds (in parentheses) targeting the trypanosomal (TcMEc; TcMEm) 
and/or human (HSME1; HsME2; HsME3) are given. Compounds were deemed inactive 
if no IC50 could be determined over the concentration range used (highest assayed 
concentration was 80 µM. * Scaffold representative of 80% of ATR3 compounds. Within 
this group compounds are also found with substituted 5-membered heterocycles attached 
at the nitrogen of sulfonamide (10% of compounds), beside other substituents connected 
to sulfonamide, as aliphatic groups. 
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Figure 3: Structure of TcME inhibitors used in phenotypic screens. Selected 
compounds were assayed against T. cruzi epimastigote and amastigote forms (Materials 
and Methods). Values of EC50 are presented in Table 1. 
 
Figure 4: SAR of groups ATR1, ATR2 and ATR6. A: Comparison among ATR1 
compounds shows the essentiality of a sulfhydryl group at position R1 for activity. B: SAR 
for ATR2 group shows that different ring systems are allowed without affecting potency 
against TcMEm. C: SAR for ATR6 group. The presence of a ring system at position R1 
gives selectivity against TcMEm, while the substitution for an amine or methoxy changes 
the selectivity towards TcMEc. When IC50 is assigned as > 80 µM, it means that no 
compound could inhibit at least 50% the enzyme activity at 80 µM (the highest assayed 
concentration).  
 
Figure 5: SAR of ATR3 group. In grey background, the most potent compounds (IC50 
< 10 nM) together with other representatives of inhibitors with IC50 below 100 nM. The 
IC50 presented is for TcMEc. The arrows indicate the related compounds from a SAR 
series. The variable position among the analogues is highlighted for each serie.     
  
 30 
Figure 1: 
 
  
 31 
Figure 2: 
 
  
 32 
Figure 3: 
 
  
 33 
Figure 4: 
 
  
 34 
Figure 5: 
 
